Case Report

Pituitary carcinomas: Rare and challenging

Georges Sinclair1,2,3, Martin Olsson1, Hamza Benmakhlouf4, Yahya Al-saffar4, Philippa Johnstone2, Mustafa Aziz Hatiboglu3, Alia Shamikh5

Departments of 1Neurosurgery, 4Medical Radiation Physics and Nuclear Medicine, 3Neuropathology, Karolinska University Hospital, Stockholm, Sweden, 4Department of Oncology, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, 3Department of Neurosurgery, Bezmialem Vakif University Medical School, Istanbul, Turkey.

E-mail: *Georges Sinclair - georges.sinclair@gmail.com; Martin Olsson - martin.j.olsson@sll.se; Hamza Benmakhlouf - hamza.benmakhlouf@gmail.com; Yahya Al-saffar - yehya.al-saffar@sll.se; Philippa Johnstone - philippa.johnstone1@nhs.net; Mustafa Aziz Hatiboglu - azizhatiboglu@yahoo.com; Alia Shamikh - alia.shamikh@sll.se

INTRODUCTION

Pituitary carcinomas (PCs) are rare malignant neoplasms, accounting for approximately 0.12% of adenohypophysal tumors and 6% of local invasive adenomas.10,16,19 According to the World Health Organization, PCs are composed of adenohypophysal cells with craniospinal or systemic metastatic activity.8,10,20 These lesions often arise from previously resected and/or irradiated infiltrating adenomas;4 yet, there are no histological criteria enabling differentiation of local invasive adenomas from those with carcinogenic potential.16 Malignant activity is usually slow and topographically wide; furthermore, around 20% of these tumors remain biochemically nonfunctional.19 Consequently, patients may remain asymptomatic for a longer period of time before the initial diagnosis. In addition to this, PCs have a tendency for complex evolution. Due to these factors mentioned, the management of PCs remains challenging, yet of the utmost

ABSTRACT

Background: Pituitary carcinomas (PCs) are defined as adenohypophysal tumors with metastatic activity within and outside the boundaries of the central nervous system (CNS). The condition is rare and therefore seldom reported; most lesions are hormone producing and have a tendency for complex evolution. As such, the management of PCs remains difficult. We present an illustrative case of PC with a brief review of the recent medical literature.

Case Description: A 58-year-old patient was diagnosed with prolactinoma in 2005. The ensuing biochemical and radiological evolution proved contentious; local tumor control was never fully achieved despite multimodal management including pharmacological treatment, repeated resections, and radiotherapy. In late 2017, the patient developed metastatic lesions within the confinements of the CNS requiring further surgical interventions, high-dose radiation, and systemic treatment.

Conclusion: As it was the case in our patient, PCs require tailored, multimodal treatments according to the degree of infiltration, site of invasion, and hormone status. Further studies are necessary to understand the mechanisms promoting “extra-sellar” activity, particularly at distant sites; the identification of biomarkers exposing the risk of PC remains a crucial aspect of diagnostics, prevention and future customized therapies.

Keywords: Adenoma, Central nervous system, Metastatic activity, Pituitary carcinoma
importance to those few affected. Here, we present an illustrative case of PC with contentious evolution, reviewing the latest developments in the fields of diagnosis and treatment.

CASE DESCRIPTION

We present a case of a previously healthy, 58-year-old male patient, who developed bitemporal hemianopsia in the first few months of 2005. The ensuing radiological assessment revealed a 22 mm × 20 mm × 15 mm pituitary mass with chiasmatic/bilateral optic nerve upward dislocation [Figure 1]; the complementary endocrine screening showed evidence of a growing prolactinoma (March 2005). Subsequent management proved complicated despite the use of pharmacological treatment, repeated surgical interventions, and the access to high-dose radiation therapy schedules. Metastatic activity was reported almost 12 years after initial diagnosis [Figures 2-4 and Table 1], remaining largely unresponsive to multimodal treatment. Despite this entangled evolution, the patient presented with symptoms of mild–moderate fatigue (Karnofsky Performance Status (KPS) 70-80) at the last follow-up (13 years after diagnosis), mostly due to ongoing antiepileptic treatment, uncontrolled prolactin levels, and chemotherapy. Table 1 describes key timeline points relevant to this case.

DISCUSSION

General aspects

Hypophyseal tumors account for 15% of all intracranial tumors; 35%–40% are locally invasive, whereas only 0.1%–0.2% are found to develop to PC. To the best of our knowledge, <200 cases of PC have been described to date. The time interval between initial diagnosis and metastatic

![Figure 1](image1.png): Top: Contrast-enhanced T1-weighted sagittal cross-sectional magnetic resonance imaging at initial diagnosis (2005). Bottom: Same study, coronal cross-section. Evidence of a 22 mm × 20 mm × 15 mm prolactinoma with chiasm/bilateral optic nerve upward dislocation.

![Figure 2](image2.png): Follow-up contrast-enhanced T1-weighted axial cross-sectional magnetic resonance imaging (November 2017) showing a 10-mm left-sided frontal lesion within the anterior limits of the falx cerebri: Suspected metastatic lesion (pituitary carcinoma).

![Figure 3](image3.png): (×400). Microscopic reassessment of samples from second metastasectomy (November 2017) for the purpose of this article (a) H&E staining: high mitotic activity in a population of large cells with atypical nuclei and prominent nucleoli. (b) Ki67: high proliferation (35%). (c) Overexpression of P53 limited to a few tumor cells (anti-p53 antibody). (d) Diffuse Immunostaining for prolactin. Of note, thyroid stimulating hormone, growth hormone, adrenocorticotropic hormone, CK-AE1AE3 proved negative. Samples from the first metastasectomy were not made available for reanalysis.
## Table 1: Key timeline relevant to this case.

| Timeline           | Treatment                                                                                                                                  | Outcome                                                                                                                                      |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| March–May 2005     | Bromocriptine mesylate presurgery                                                                                                           | No biochemical or clinical response                                                                                                         |
| June–July 2005     | Cabergoline treatment due to further increase in Prolactin                                                                                 | Minor visual improvement the following 10 months. MRI unchanged, no substantial decrease in levels of prolactin                               |
| May 2006           | First transsphenoidal hypophysectomy                                                                                                         | Histology reported as benign prolactinoma (Ki67 – 2%, low mitoses)*. Further visual improvement and decrease of prolactin (to 137 μg from 1500 μg presurgery) |
| August 2006        | Bromocriptine mesylate reinstated (Adjuvantic)                                                                                                | Prolactin elevation to 423 μg. MRI: tumor regrowth in the sella and around the hypophyseal stalk                                               |
| April 2007         | Second transsphenoidal surgery                                                                                                              | Histology reported as benign prolactinoma (Ki67 – 4%, low mitoses)*. Rapid decrease of prolactin levels (from >400 to 150 μg); hormonal substitution with cortisol, testosterone, and thyroxine required (postsurgery) |
| September–December 2007 | • MRI: 8-mm tumor next to the hypophyseal stalk (Lesion 1) + 10-mm lesion within the left cavernous sinus (Lesion 2). Levels of prolactin unchanged  
  • Lesions 1 and 2 treated with GKRS (20 Gy and 26 Gy, respectively)  
  • Bromocriptine disrupted and cabergoline reinstated                                      | Prolactin dropping to 120–140 μg post GKRS. Stable biochemical and radiological evolution under 2008                                      |
| October 2009       | Lesion 2 retreated with GKRS (20 Gy) due to MRI-confirmed relapse and gradual increase in prolactin levels during the course of 2009 (up to 222 μg) | Stable biochemical and radiological evolution under 2010 and most of 2011                                                                    |
| October 2011–February 2013 | Sequential chemotherapy (lomustine followed by TMZ) due to recurrence of L1 and L2                                                        | No response to chemotherapy, further tumor growth                                                                                             |
| March–April 2013   | First transcranial tumor resection followed by prophylactic proton beam radiation to the surgical cavity                                  | Histology confirms relapsing prolactinoma (Ki67 – 17%, increasing number of mitoses)*. Stable biochemical and radiological evolution up to November 2017 |
| November 2017      | Second transcranial tumor resection due to 10-mm left-sided frontal lesion within the confines of the falx                                  | PC histologically confirmed according to (i) available medical notes and (ii) reanalysis of the previously collected samples [Figures 2 and 3]** |
| January–May 2018   | • Follow-up MRI [Figure 4]: 4–5 mm right-sided frontobasal metastasis (Lesion 3) + 6–7 mm lesion within the limits of the chiasm (Lesion 4)  
  • Lesion 3 treated with GKRS (25 Gy); Lesion 4 not treated due to potential post-GKRS visual impairment  
  • Prophylactic radiation to the surgical region in the falx (LINAC, 30Gy in 5 fractions)       | Gradual increase in levels of prolactin despite radiotherapy (up to 12800 μg, April 2018)                                                |
| June–September 2018 | Treatment with somatostatin analog                                                                                                          | MRI-confirmed tumor growth in the sella; prolactin-levels up to 22080 μg despite treatment                                                 |
| October 2018       | Started chemotherapy carboplatin/Taxol                                                                                                       | Outcome not reported                                                                                                                          |

*Data based on previous medical notes; further immunohistochemical data could not be found. **Immunohistochemical reanalysis for the purpose of this case report. PC: Pituitary carcinoma, MRI: Magnetic resonance imaging, GKRS: Gamma knife radiosurgery, LINAC: Linear accelerator, TMZ: Temozolomide
activity has been reported to range from 0.3 to 18 years (mean = 6.6 years/median = 5.0 years).

As demonstrated in our case description, prognosis remains poor and <50% of PC patients survive the 1st year of metastatic disease.

Clinical characteristics

PC activity prevails in central nervous system (CNS) locations although other sites of dissemination such as the liver, bone, heart, ovaries, and lymph nodes have also been reported. Blood-borne sella dura infiltration as well as postoperative drop metastasis and cerebrospinal fluid spreading have been described as the main pathways of CNS dissemination. As many as 80%–88% of all PC tumors are hormone active, among these, prolactin (as in our case) and adrenocorticotropic hormone (ACTH) production are foremost reported, accounting for almost 50% of all PCs. Despite its limited representation in numbers among hormonally active pituitary adenomas, ACTH-secreting PCs exhibit a preponderant rate of systemic infiltration. Growth hormone (GH), luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone have also been described, yet to a less frequent extent. When symptoms appear, it is often the result of an endocrine disturbance and a mass effect due to the latter-described conditions. As expected, visual impairments, headaches, and hormone-related symptoms are often present; yet, as previously illustrated in the present case, other symptoms may arise depending on the site and growth dynamics of the underlying metastatic activity. Ultimately, some groups have associated frequently recurring adenomas to metastatic spread.

Immunohistochemistry

As is the case here, a thorough microscopic tumor evaluation from the primary and metastatic sites remains crucial in confirming diagnosis and assessing best treatment options. Histologically, PC lesions may look like typical adenomas but may also display marked pleomorphism and frequent mitoses. In this contentious environment, some groups have reported atypical cellular morphology, higher mitotic activity (Ki-67/MIB-index), and p53 tumor suppressor gene as variables predisposing to the development of PCs. In our case, the consecutive rise of the Ki-67 and its underlying mitotic activity at each surgery may have been indicators of the events to come. Zemmoura et al. identified angiogenesis, vascular invasion, gene upregulation, and allelic loss of chromosome 11 as potential factors of promalignancy in prolactinomas. Metastatic development has also been associated with increased activity of Bcl-2 modulated telomerase, topoisomerase-2-α, cyclooxygenase-2, and galectin-3. Other groups have theorized on the use of less common markers such as p27, Ras, the retinoblastoma gene, MEN-1, gsp, nm23, and HER2/neu; yet, their rare prevalence renders their interpretation and use difficult. Finally, studies have focused on identifying genetic differences between invasive and noninvasive tumors. Galland et al. confirmed the overexpression of 4 genes common to adenomas and metastatic activity (IGFBP5, MYO5A, FLT3, and NFE2L1), in this context, being precursors of tumor cell migration. Particular interest has also been paid to MYO5A expression.

Treatment modalities of manifest PC

The treatment of PCs remains multimodal and includes surgical resection (transsphenoidal and transcranial), linear accelerator (LINAC)- and proton-beam-based fractionated radiotherapy, single-dose GKRS, chemotherapy, immunotherapy, and the use of other pharmacological agents targeting hormone production itself. Although treatments are customized according to metastatic deployment and biochemical status, their effects on overall disease activity remain poor, as demonstrated by the present clinical case. In recent years, positive results in several patients with PC have been reported using the alkylating agent temozolomide (TMZ). Paradoxically, some studies have
highlighted a more favorable evolution of tumors with a lower immunorexpression of O-6-methylguanine-DNA methyltransferase (MGMT) while an intermediate-to-high MGMT expression appears to be associated with TMZ resistance.$^{[6,10,14]}$ In the context of glioblastoma multiforme, the methylation of the MGMT promoter is strongly associated with a better outcome when using TMZ; however, validation of the methylation status in the framework of PC remains unclear.$^{[14]}$ In the present case, TMZ did not prove effective although data concerning the methylation status of the tumor were unavailable. Other groups have theorized on the application of a range of alternative agents including mTOR inhibitors (rapamycin ± somatostatin analog) and R-roscovitine (CDK2/Cyclin E inhibitor) for ACTH tumors and anti-VEGF antibody treatment and EGF receptor (Erb1 and Erb2) tyrosine kinase inhibitors for dopamine-resistant prolactinomas.$^{[3,6]}$ Finally, promising results have been reported using isotope-labeled somatostatin analogs; however, further studies regarding their short- and long-term efficacy are warranted.

**CONCLUSION**

PCs are rare neoplasms with contentious metastatic evolution and require multimodal, tailored treatments. Unfortunately, despite modern medical technology, the prognosis remains poor. Although the incidence of PCs is low, further studies are necessary to understand the proliferative mechanisms leading to local invasion and metastatic activity. The identification of prognostic biomarkers for risk stratification and treatment response remains necessary in terms of prevention of PCs and future selected therapies.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

None.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. AbdelBaki MS, Waguespack SG, Salceda V, Jones J, Stapleton SL, Baskin DS, et al. Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: A pediatric case report and review of the literature. J Neurooncol 2017;135:213-5.
2. Balili I, Sullivan S, McKeever P, Barkan A. Pituitary carcinoma with endolympathic sac metastasis. Pituitary 2014;17:210-3.
3. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 2010;70:666-74.
4. Dudziak K, Honegger J, Bornemann A, Horger M, Mussig K. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course case report and review of the literature. J Clin Endocrinol Metab 2011;96:2665-9.
5. Galland F, Lacroix L, Saulnier P, Dessen P, Meduri G, Bernard M, et al. Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer 2010;17:361-71.
6. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, et al. New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 2012;15:37-43.
7. Landman RE, Horwich M, Peterson RE, Khandji AG, Wardlaw SL. Long-term survival with ACTH-secreting carcinoma of the pituitary: A case report and review of the literature. J Clin Endocrinol Metab 2002;87:3084-9.
8. Lloyd RV, Osamura YR, Kloppeg G, Rosai J. In: Organization WH, editor. WHO Classification of Tumours of Endocrine Organs. Lyon: IARC; Press; 2017.
9. Maira G, Doglietto F. Pituitary carcinoma: A devastating disease in need of an earlier diagnosis and of effective therapies. World Neurosurg 2013;80:e143-5.
10. Morokuma H, Ando T, Hayashida T, Horie I, Inoshita N, Murata F, et al. A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment. Case Rep Endocrinol 2012;2012:645914.
11. Park KS, Hwang JH, Hwang SK, Kim S, Park SH. Pituitary carcinoma with fourth ventricle metastasis: Treatment by excision and gamma-knife radiosurgery. Pituitary 2014;17:514-8.
12. Philippin M, Morange I, Barrie M, Barlier A, Taieb D, Dufour H, et al. Long-term control of a MEN1 prolactinoma after temozolomide treatment: Ann Endocrinol (Paris) 2012;73:225-9.
13. Phillips J, East HE, French SE, Melcescu E, Hamilton RD, Nicholas WC, et al. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Hormones (Athens) 2012;11:477-82.
14. Raverton G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: A French multicenter experience. J Clin Endocrinol Metab 2010;95:4592-9.
15. Sansur CA, Oldfield EH. Pituitary carcinoma. Semin Oncol 2010;37:591-3.
16. Scheithauer BW, Kovacs K, Nose V, Lombardero M, Osamura YR, Lloyd RV, et al. Multiple endocrine neoplasia Type 1 associated thyrotropin-producing pituitary carcinoma: Report of a probable de novo example. Hum Pathol 2009;40:270-8.
17. Shastri BR, Nanda A, Fowler M, Levine SN.
Adrenocorticotropic hormone-producing pituitary carcinoma with intracranial metastases. World Neurosurg 2013;79:404. e11-6.

18. Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E, et al. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci 2017;41:75-7.

19. Tufton N, Roncaroli F, Hadjidemetriou I, Dang MN, Dénes J, Guasti L, et al. Pituitary carcinoma in a patient with an SDHB mutation. Endocr Pathol 2017;28:320-5.

20. Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, François P, et al. Aggressive and malignant prolactin pituitary tumors: Pathological diagnosis and patient management. Pituitary 2013;16:515-22.

How to cite this article: Sinclair G, Olsson M, Benmakhlouf H, Al-Saffar Y, Johnstone P, Hatiboglu MA, et al. Pituitary carcinomas: Rare and challenging. Surg Neurol Int 2019;10:161.